Ovizio offers cutting-edge automated cell-monitoring solutions tailored for the cell & gene therapy, vaccine industry, and broader life sciences applications. Their unique technology, grounded in patented differential digital holography, enables easy-to-use, label-free, and non-invasive three-dimensional imaging of living cells.
The company's advanced systems can efficiently track cell density, morphology, viability, viral infection kinetics, and activation status, making them essential tools for both R&D and manufacturing settings. In addition to improving quality, Ovizio's microscopes offer potential for significant cost reduction across applications.
Founded in 2010 and headquartered in Belgium, Ovizio operates at the intersection of AI, Biotechnology, Life Sciences, Medical Devices, and VR/AR. Their most recent financial boost came as a €50.00K grant from EASME - EU Executive Agency for SMEs in 2017.